HEPATOCELLULAR CARCINOMA (HCC)

This study is for people with a type of liver cancer that cannot be removed by surgery. It tests a treatment plan that starts with a targeted radiation procedure (TARE) using tiny glass beads, followed by two drugs (durvalumab and bevacizumab) that help the immune system fight th…

This study looks at how well a treatment called 90Y radioembolization works for people with early-stage liver cancer. About 200 patients in Korea will be followed to see how their tumors respond, how long they live, and what side effects occur. The goal is to gather real-world da…

This study tests a new, more stable mixture of chemotherapy drug and iodized oil for treating early-stage liver cancer in people who cannot or choose not to have surgery. The treatment combines TACE (a procedure that blocks the tumor's blood supply and delivers chemo directly) wi…

This phase 3 trial tests whether a combination of two drugs (camrelizumab and rivoceranib) can prevent liver cancer from returning in patients who have a high risk of recurrence after surgery or ablation. About 687 participants will either receive the drug combination or be close…

This study tests a combination of two drugs (toripalimab and bevacizumab) along with three different artery-directed treatments for people with liver cancer that cannot be removed by surgery. The goal is to see which artery treatment works best with the drug combo to shrink tumor…

This study tests two immunotherapy drugs, cobolimab and dostarlimab, together in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The …

This early-stage study tests whether adding two drugs (JS014 and Toripalimab) to a standard liver cancer procedure (TACE) is safe and helps control tumors. About 20 adults with liver cancer that cannot be removed by surgery will take part. The main goal is to check for side effec…

This study tests a new drug combination (QL1706 plus local therapy or targeted drugs) in 62 adults with liver cancer that worsened after initial targeted-immunotherapy. The goal is to see if this second-line approach can shrink tumors and control the disease. Participants receive…

This early-phase study was designed to test a new treatment combination for people with advanced liver cancer that can be surgically removed. Participants would have received three sessions of focused radiation to the tumor, along with immunotherapy drugs (one dose of tremelimuma…

This study compares a shorter, faster MRI scan to the standard ultrasound for detecting liver cancer in 820 adults with liver cirrhosis. Researchers will also check if blood markers can help spot cancer. The goal is to see if the abbreviated MRI is more accurate and cost-effectiv…

This study tests whether a liver cancer treatment called Y90 radioembolization can be safely done in one day instead of two for people with small tumors (less than 5 cm). The usual two-day process includes a mapping step that may not be needed for these patients. The goal is to s…

This study collects fresh tumor samples from 416 adults with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) to develop and train a live tumor diagnostic platform. The goal is to see how accurately the platform can predict whether a pa…

This study looks back at 500 people with liver cancer that was too large to remove at first. After a mix of treatments (TACE, lenvatinib, and an immunotherapy drug), their tumors shrank enough to consider surgery. Researchers will use scans and medical records to see if certain p…